• BDO Corporate Finance successfully assisted Labo Van Poucke’s shareholders on the sale of their shares to Eurofins Scientific.
Case study:

BDO Corporate Finance successfully assisted Labo Van Poucke’s shareholders on the sale of their shares to Eurofins Scientific.

05 March 2018

BDO Corporate Finance successfully assisted the shareholders of Labo Van Poucke (LVP), a leading laboratory performing human medical testing covering all branches of clinical biology, on the sale of their shares to Eurofins Scientific.

Labo Van Poucke, before the transaction a 100% family-owned laboratory, was founded in 1969. LVP performs testing for hematology, serology, chemistry, immunology, microbiology and molecular biology, offering almost all medical analyses commonly requested by general practitioners and specialists. LVP is licensed by the Belgian Scientific Institute of Public Health, or WIV-ISP, for clinical pathology testing, as well as by the Belgian Federal Agency for Nuclear Control, or FANC, for isotopic tests. It has been accredited by the Belgian Accreditation Body, BELAC, since 1997, and operates in compliance with the ISO 15189 standard for medical laboratories. LVP employs 34 staff and generated close to EUR 5m in revenues in 2017.

Eurofins Scientific is a global leader in bio-analytical testing, and a key player in the European clinical diagnostics market. The company has over 30.000 employees in 400 laboratories across 42 countries. The acquisition of LVP will give Paris-based Eurofins an entry platform into the clinical testing market in Belgium, as well as a license to operate and sell in that market, Eurofins CEO Gilles Martin said in a statement. Further information can be found in Eurofins’ press release